Potential new biomarker for colon cancer
CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences
Full Post: Surface analysis exposes counterfeit medicines
Cincinnati scientists have identified a new biomarker that could help predict a person’s risk of developing colon cancer and how aggressive it may become.
The University of Cincinnati (UC) team has identified “hotspots”-areas of deleted genetic data-that play a critical role in regulating gene expression and influence colon cancer progression. Researchers speculate that these hotspots could be used as a biomarker for colon cancer.
They report their findings in the Jan. 16, 2009, issue of PLoS Genetics . This study is the first to explain how a gene-AMACR-is regulated in relation to cancer development and to identify specific genetic events (a polymorphism and somatic cell mutations) related to colon cancer.
For this study, UC researchers looked at the actions of the AMACR gene in human tissue. AMACR breaks down branched-chain fatty acids, a type of molecule only found in animals that eat plants. Previous research showed that plant-derived fatty acids, such as those found in red meat and dairy products, can accelerate cancer growth.
“From the colon tissues, we’ve identified two types of genetic deletions that may allow us to predict whether people will have a good or bad cancer outcome,” says Xiang Zhang, PhD, first author of the study and UC environmental health research associate. “If a person carries one of the deletions, it may predispose him or her to a more aggressive type of colon cancer.”
UC researchers analyzed the AMACR gene’s abnormal expression patterns using a sophisticated laser-capture microdissection technique to identify the key biological events that lead to colon cancer progression. They also compared gene sequencing data from the general population-obtained from whole blood samples-to that of the human colon cancer tissue samples.
In addition to discovering the hotspots that trigger abnormal AMACR expression, they also identified specific proteins (transcription factors) that would normally bind to the deleted sequences to maintain normal gene expression.
“Our hope is that this new knowledge will help us develop better diagnostic tools for colon cancer,” says Zhang.
Researchers say this discovery could also help people make strategic lifestyle choices to reduce their risk for developing colon and other cancers from a gene-environmental interaction.
“For years, scientists have believed that a diet including a large amount of red meat and low in fiber may lead to increased risk for colon cancer, but it’s not that linear,” says Shuk-mei Ho, PhD, senior author of the study and chair of UC’s environmental health department. “We need to start paying closer attention to how the environment we live in and the things we put in our bodies interact with our genetic makeup to influence our cancer risk.”
The UC research team expects to expand this research into a multi-center study in the near future. The project is currently funded by the National Institutes of Health and U.S. Army Prostate Cancer Program.
Cancer researchers at the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit? Medizin Berlin (Germany) have identified a gene which enables them to predict for the first time with high probability if colon cancer is going to metastasize. Assistant Professor Dr. Ulrike Stein, Professor Peter M. Schlag, and Professor Walter Birchmeier
Full Post: Scientists find gene that is a powerful predictor of colon cancer metastasis
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens. “These findings have important implications for individualizing therapy,” said Katherine Garman, M.D., a gastroenterology fellow
Full Post: New model predicts risk of recurrence in early stage colon cancer patients
Cancer and cell biology experts at the University of Cincinnati (UC) have identified a new tumor suppressor that may help scientists develop more targeted drug therapies to combat lung cancer. The study, led by Jorge Moscat, PhD, appears in the January 2009 issue of Molecular and Cellular Biology . Proto-oncogenes are genes that play a
Full Post: Discovery of new tumor suppressor for lung cancer
Common genetic polymorphisms induce major differentiations in the metabolic make-up of the human population, according to a paper published November 28 in the open-access journal PLoS Genetics. An international team of researchers, led by Karsten Suhre, has conducted a genome-wide association study with metabolomics, identifying genetic variants in genes involved in the breakdown of fats.
Full Post: Study identifies genetic variants giving rise to differences in metabolism
The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy. Hormone-related therapy is the first line of treatment for more advanced prostate
Full Post: Theraputic target for prostate cancer